Bayer HealthCare Pharmaceuticals has notified the FDA that the company will begin removing the remaining Trasylol stock from US market, most of which is in warehouses and hospital or physician's stock.
Baxa Corporation has won two Colorado Business Marketing Association Awards for its integrated direct mail campaign featuring the PadLock® Set-Saver product - Best Strategy and Gold Key for Best B2B campaign (less than $50,000). The campaign focused on the product's
Black & Asian business travellers from the UK could be exposing themselves to the deadly disease, malaria, after a new survey revealed that 50% of travellers who originate from a malarious area believe they have natural immunity when travelling to
Thousands of UK residents could be exposing themselves to the potentially deadly disease, malaria, a new survey reveals today. (PRWeb May 15, 2008) Read the full story at http://ww1.prweb.com/releases/2008/05/prweb939424.htm
Akorn-Strides has announced the approval of an abbreviated new drug application for flumazenil injection USP, 0.1mg/mL, packaged in 5mL and 10mL multiple dose vials, which is indicated for the complete or partial reversal of the sedative effects of benzodiazepines.
Biophan Technologies, a developer of next-generation biomedical technology, has acquired the patent portfolio of Nanoset, a private company and technology collaborator.
ImClone Systems has announced that a Phase II clinical trial of IMC-A12, the company's fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced liver cancer has opened for patient enrollment.
PhotoMedex has received FDA 510k clearance to market the new, more powerful, faster Xtrac Velocity excimer laser system to treat psoriasis, vitiligo, atopic dermatitis and leukoderma.
Spinal Restoration has announced that the FDA has approved an investigational device exemption pilot study of the Biostat Disc Augmentation System. Enrollment in the 15 patient pilot study is expected to begin at three clinical sites in July, 2008.
AVI BioPharma has announced that treatment of non-human primates with either the antisense drug AVI-6002 or with the antisense drug AVI-6003, resulted in a reproducible and high rate of survival in the face of an otherwise lethal infection with Ebola
Qiagen and Geneart have announced their collaboration to develop, produce and commercialize a new product line for the enhanced production of all 35,000 human proteins.
St Jude Medical has announced the initial enrollments into a new landmark clinical trial designed to better identify which patients could benefit from implantable cardioverter defibrillator therapy for the prevention of sudden cardiac arrest.
Medimetriks Pharmaceuticals has commenced operations. The newly-formed company will develop, license and commercialize innovative prescription products for the dermatology and podiatry marketplaces.
Covidien has announced the European introduction of the AbsorbaTack 5mm absorbable mesh fixation device for hernia repair, one of the most performed surgical procedures worldwide.
Xtent has announced positive six-month follow-up data from the Custom III clinical trial, which assessed the safety and efficacy of the Custom NX drug eluting stent system for the treatment of patients with coronary artery disease.
StemCor Systems has received a National Institutes of Health Phase I Small Business Innovation Research Grant to further develop the MarrowMiner, which recently received 510(k) clearance from the FDA for harvesting bone marrow.
